The 15d-PGJ$_2$ hydrogel ameliorates atopic dermatitis through suppression of the immune response

MARCELO H. NAPIMOGA$^1$, JULIANA T. CLEMENTE-NAPIMOGA$^1$, NINA M. MACHABANSKI$^1$, MARIA EDUARDA A. JULIANI$^1$, PEDRO HENRIQUE B. C. ACRAS$^1$, CRISTINA G. MACEDO$^1$, HENRIQUE B. ABDALLA$^2$, ANTÔNIO JOSÉ DE PINHO Jr$^3$, ANDRESA B. SOARES$^3$, MARCELO SPERANDIO$^3$ and DANIELE R. DE ARAÚJO$^4$

$^1$Laboratory of Immunology and Molecular Biology, São Leopoldo Mandic Institute and Research Center, Campinas, São Paulo 13045-755; $^2$Laboratory of Orofacial Pain, Department of Physiology, Piracicaba Dental School, State University of Campinas, Piracicaba, São Paulo 13414-903; $^3$Department of Oral Pathology, São Leopoldo Mandic Institute and Research Center, Campinas, São Paulo 13045-755; $^4$Center of Human and Natural Sciences, Federal University of ABC, Santo André, São Paulo 09210-580, Brazil

Received October 3, 2018; Accepted January 15, 2019

DOI: 10.3892/mmr.2019.10156

Abstract. The present study examined the efficacy of the topical 15d-PGJ$_2$-poloxamer 407 hydrogel in an atopic dermatitis (AD) animal model. The 15d-PGJ$_2$ hydrogel was prepared and characterized. The examined rats possessed AD-Like cutaneous lesions, which were induced using 2,4-dinitrochlorobenzene, the rats were then treated with a hydrogel vehicle, 15d-PGJ$_2$ hydrogel or tacrolimus for 14 days. The rats were sacrificed and blood samples were collected to quantify the IgE levels. Subsequently, skin biopsies were stained with toluidine blue to identify mast cells and immunohistochemistry was performed for ROR-γt and TNF-α. Histological analyses demonstrated that 15d-PGJ$_2$ hydrogel significantly decreased mast cell infiltration (P<0.05) when compared with the AD-group. Tacrolimus at 0.1% exhibited decreased mast cell infiltration; however, this difference was not statistically significant from the AD-group. Topical 15d-PGJ$_2$ hydrogel and Tacrolimus 0.1% significantly reduced the serum levels of IgE (P<0.05) compared with the AD-group. Immunohistochemistry revealed a significant decrease in ROR-γt and TNF-α positive cell expression (P<0.05) in the 15d-PGJ$_2$ hydrogel group compared with the AD-group. In summary, topical administration of 15d-PGJ$_2$ hydrogel had a beneficial effect on AD symptoms, suggesting that this formulation may be a useful strategy for the treatment of AD.

Introduction

Atopic dermatitis (AD) is a highly pruritic cutaneous disease from an inflammatory background that affects up to 10% of adults and 25% of children (1). The skin of AD-sufferers may feature intense research is underway to develop new pharmacological strategies to tackle AD. Since the range of drug-based options to treat AD is limited, would represent a superior option in the management of AD.
by albumin-induced catalysis, generating several other derivatives, including 15-deoxy-12,14-PGJ₂ (15d-PGJ₂) (7). Similarly to other PGs, 15d-PGJ₂ can be actively transported into cells to promptly bind nuclear receptors and modify intracellular signaling factors, thanks to a highly reactive cyclopentenone ring (8). It has been demonstrated that 15d-PGJ₂ may be the basis for promising strategies to tackle a variety of inflammatory diseases (9,10). AD is also characterized by mast cell dehydrate to yield biologically active cyclopentenone PGs, such as 15d-PGJ₂ (11).

Considering the anti-inflammatory potential of 15d-PGJ₂, the aim of this study was to test the effectiveness of topical thermoreversible 15d-PGJ₂-poloxamer (PL) 407 hydrogel formulation in the 2,4-dinitrochlorobenzene (DNCB)-induced AD animal model.

Materials and methods

Preparation and physico-chemical characterization of 15d-PGJ₂ hydrogel. PL 407 hydrogels at 30% w/w were dispersed in deionized water at 4°C by magnetic stirring (150 rpm) for 12 h until complete dissolution. 15d-PGJ₂ was then solubilized in dimethyl sulfoxide (DMSO) and dispersed into the hydrogel at 15 ng/µl. The final DMSO concentration into the hydrogels was 0.015%, which is sufficiently low to avoid skin toxicity.

The 15d-PGJ₂-micelle interaction and micellar self-assembly were investigated using dynamic light scattering ([DLS; Nanoseries Zetasizer ZS-Malvern® particle analyzer (Malvern Instruments, Ltd., Malvern, UK)] for determining the micellar hydrodynamic diameter and mean distribution size. For samples preparation, PL or PL-PGJ₂ systems (3% w/v) were filtered across a polycarbonate membrane (pore 0.22 µm) and measurements acquired at least three times for sample at a fixed 173° angle, at 25°C to 37°C.

Drug loading (DL, %) and entrapment efficiency (EE, %) parameters were determined for 3% PL micellar formulation. Aliquots (100 µl) were diluted in 0.02 M monobasic sodium phosphate pH 3.5/acetonitrile (60/40% v/v) solution and analyzed by HPLC method. DL, % (Eq. 1) and EE, % (Eq. 2) were determined as follow:

\[
DL(\%) = \frac{C_{PGJ2} \text{ in micellar phase} / C_{PL \text{ in micellar sample}}} \times 100
\]

\[
EE (\%) = \frac{C_{(PGJ2 \text{ in micellar phase} / C_{\text{total}} \text{ in samples}} \times 100
\]

where C_{PGJ2} is 15d-PGJ₂ concentration, C_{PL} is PL concentration, and C_{total} is the total PGJ₂ concentration into the samples.

Differential Scanning Calorimetry (DSC) was performed to determine temperature and enthalphy relative to micellization. The hydrogels (30 mg) were placed in sealed aluminum receptacles and underwent three heating-cooling cycles (0 to 50°C) at 5°C/min in a DSC equipment (Q-200; TA Instruments, New Castle, DE, USA). An empty receptacle was used as negative control. All thermograms were described as heat flux (cal/g) against temperature (°C).

The sol-gel transition temperature (Tsol-gel) and gelation kinetics were determined by an oscillatory rheometer (Kinexus Lab., Malvern Instruments, Ltd.) with a cone-plate geometry, under a temperature range from 10 to 50°C and frequency at 1 Hz. From the results, parameters related to the elastic (G'), viscous modulus (G'') and viscosity (η) were obtained and data analyzed by rSpace for Kinexus® software.

For investigating the 15d-PGJ₂ release mechanisms from PL hydrogel, in vitro assays were carried out using a vertical two-compartment diffusion model Franz-type cells (1.76 cm² area, Microette Plus®, Hanson Research, Chatsworth, CA, USA). An artificial membrane (cellulose acetate sheets, MWCO 1000 Da, Spectrum Lab) was used as a barrier for separating the two compartments. The donor compartment was filled with 250 µl of 15d-PGJ₂ (in ultrapure water) or PL404-PGJ₂. 15d-PGJ₂ final concentration of 3.75 µg/250 µl for both formulations. Receptor compartment was filled with 7.0 ml of 5 mM Hepes, 154 mM NaCl buffer (pH 7.4, at 37°C) and maintained under magnetic stirring (350 rpm). Aliquots of 1.0 ml were withdrawn from the receptor compartment at intervals from 0.5 to 24 h. Samples were analyzed by HPLC. Data were expressed as 15d-PGJ₂ released percentage against time (h).

Release profiles were then analyzed according to Zero-order (Eq. 3), Higuchi (Eq. 4) and Hixson-Crowell (Eq. 5) models, as described below:

\[
Qt=Q_0 + K_t t \quad \text{(Eq. 3)}
\]

where Qt is the cumulative amount of drug released at time t, Q₀ is the initial amount of drug, K₉ is the zero-order release constant, and t is time.

\[
Qt=K_{Hi} t^{1/2} \quad \text{(Eq. 4)}
\]

where the rate of drug release is linear as a function of square root of time and the drug is the only component that diffuses through the medium, which the release mechanism is a diffusion process dependent on Fick law. K₉ is the release coefficient, and Qt is the drug released amount.

\[
Q_0^{1/3} - Q_t^{1/3} = K_{HC} t \quad \text{(Eq. 5)}
\]

Q₀ is the initial amount of drug, Qₜ is the cumulative amount of drug released, K_{HC} is the release constant and t is time.

HPLC method for 15d-PGJ₂ quantification. The 15d-PGJ₂ quantification was performed by High Performance Liquid Chromatography (Ultimate 3000 with Chromelope 7.2 software; Dionex Corporation, Sunnyvale, CA, USA) system composed of quaternary pump, DAD detector and C18 column (150x4.6 mm, 5 µm-Phenomenex). Samples were detected at 216 nm, 0.6 ml/min flow rate (25°C) and mobile phase composed of 0.02 M monobasic sodium phosphate pH 3.5/acetonitrile (60/40% v/v). Drug retention time was 2.8 min. A calibration curve was obtained from standard solutions (2.5, 5, 50, 250 and 300 ng/ml). The detection (LOD) and quantification (LOQ) limits values were 0.063 and 0.189 ng/ml, respectively, obtained from the previously determined equation (y=0.8378 x + 3.339, R²=0.989).

Animals. This study was performed on male Wistar rats weighing 200 to 300 g (n=5/per group) and kept in cages.
(5 per cage) in a temperature-controlled room (23±1°C), 12:12 light cycle, with water and food ad libitum. All animals were obtained from the Multidisciplinary Center for Biological Investigation on Laboratory Animal Science (CEMIB-UNICAMP) and the experimentation was approved by the Committee on Animal Research of the University of Campinas (approval no. 4088-1), which followed the guidelines by the Brazilian National Council for Control of Animal Experimentation (CONCEA).

**Inducing AD-Like Lesions and 15d-PGJ2 hydrogel treatment.** Induction of AD-like lesions was adapted from previously published guidelines (12). The DNCB is an aromatic hydrocarbon that when directly applied in the skin induce an inflammation. The skin from the dorsum of the rats was shaved to an area of 1x1 cm and painted once with 200 µl of 1% DNCB. Two weeks after sensitization, the target area on the skin was challenged with 200 µl of 0.2% DNCB solution twice weekly for 2 weeks. Subsequently, one of the following treatments was topically applied once daily over 14 days: i) No treatment; ii) vehicle (PL-407, 3 µl); iii) 15d-PGJ2, hydrogel (75 ng/3 µl) or iv) Tacrolimus 0.1% (Taric® 0.1%, Tacrolimus Monohydrate; Libbs Pharmaceutics, São Paulo, Brazil). The treatments were maintained at the site of lesion induction. When the experiment was complete, the animals were sacrificed by CO2 inhalation and skin biopsies were harvested. The AD-protocol is summarized in Fig. 1.

**Histological analysis.** A portion of the skin biopsies were fixed in neutral formalin and paraffin-embedded. Seven-micrometer tissue sections were taken and stained with toluidine blue for mast cell count.

Initial analysis of the toluidine blue sections were performed by four examiners (ABS, NM, MJ, PA) using a multi-headed microscope. Toluidine blue staining was evaluated both qualitatively and quantitatively. Qualitative analysis was performed via cell positivity in all areas of the section. Quantitative analysis of mast cells was performed by positive cell counting within the subepithelial connective tissue over 10 fields per case at magnification, x400 (x40 objective lens, field diameter of 0.44 mm) using a CCD camera on a Nikon Eclipse Ci microscope. Epithelial cells were not taken into account for ROR-γt and TNF-α expression. The individual who performed the counting was blind to the experimental groups.

**Blood sample collection and IgE quantification.** Whole blood was collected by cardiac puncture to quantify IgE levels following 15d-PGJ2 hydrogel administration. The blood samples were stored in EDTA Vacutainer tubes containing EDTA (BD Biosciences, Franklin Lakes, NJ, USA) and blood plasma was then isolated. IgE measurements were obtained using ELISA following the manufacturer's instructions (BD Biosciences) via optical density (O.D.) measured at 450 nm and the readings were expressed as pg/ml, according to the standard.

**Statistical analysis.** To determine if there were significant differences (P<0.05) among groups, the data were analyzed using one-way analysis of variance (ANOVA) with post hoc contrasts using the Tukey's test. Data are presented in figures as mean ± standard deviation (SD). All statistical calculations were performed on GraphPad Prism 6® (GraphPad Software, Inc., La Jolla, CA, USA).

**Results**

**Physico-chemical characterization of PL 407 micelles and hydrogel.** The hydrodynamic diameter was the parameter used for evaluating the PL 407 micelles formation in the presence or absence of 15d-PGJ2. In general, there were no overall significant changes on micellar hydrodynamic diameter for PL407 systems after 15d-PGJ2 incorporation. Micellar diameters of ~60 nm (average distribution of 88.1±0.7%) and ~5 nm (12.1±0.2%) were observed at 25°C, while at 37°C, micellar dimensions were reduced to ~30 nm with 99.6±0.7% and polydispersion values of ~0.25, showing the influence of temperature variation on micellar self-assembly, even in the presence of 15d-PGJ2. For DL % and EE % parameters were obtained values of 44.1±0.2 and 98.5±0.3%, respectively, indicating that PL407 micelles are able to carry high amounts of 15d-PGJ2.

Calorimetric analysis (Table I) showed that micelles formation is an endothermic process (enthalpy values greater than zero), with micellization temperature (Tm) at 17.8 and 15.2°C, before and after 15d-PGJ2 incorporation. Even slightly different Tm was observed for 15d-PGJ2-PL407 system presented high enthalpy variation (ΔH˚=0.31 cal/g) than that observed for PL407 isolated system (ΔH˚=0.21 cal/g).

For PL-based formulations, the rheological behavior provides essential information to study the hydrogel formation and the influence of incorporated molecules into its structure. For this reason, rheological parameters such as elastic (G') and viscous (G'') moduli, viscosity (η) and Tsol-gel (when the most pronounced viscosity variation is observed) were determined before and after 15d-PGJ2 insertion (Table I). Fig. 2 presents the rheograms for PL407 and PL407-15d-PGJ2 under temperature variation. The incorporation of 15d-PGJ2 did not, significantly, shift the Tsol-gel, but evoked pronounced changes on elastic modulus (G') reaching values ~10 times higher than that observed for G'.
As demonstrated in Fig. 3 and Table II, the 15d-PGJ$_2$ release profiles and their mathematical models. The 15d-PGJ$_2$ release from aqueous solution reached a maximum release percentage after 4 h. On the other hand, the 15d-PGJ$_2$ released from PL407 hydrogels was sustained and lower drug release percentages were observed until 24 h (62.3%), when compared to 15d-PGJ$_2$ in solution (100%). In general, low release constant ($K_{rel}$) values were obtained for PL407-PGJ$_2$ (1.4%.h$^{-1}$; 10.4%.h$^{-1/2}$; 0.15%.h$^{-1/3}$ for Zero Order, Higuchi and Hixson-Crowell models, respectively) in relation to 15d-PGJ$_2$. However, the Hixson-Crowell mathematical model showed the highest correlation coefficient value ($R^2$=0.97) compared to Zero Order ($R^2$=0.95) and Higuchi ($R^2$=0.91).

15d-PGJ$_2$ hydrogel decreases infiltration of mast cells into AD-like skin lesions. To establish whether 15d-PGJ$_2$ hydrogel...
reduces mast cell infiltration into AD-like skin lesions, toluidine blue staining was performed on the skin biopsies following topical administration of 15d-PGJ$_2$ or vehicle (Fig. 4). Mast cell infiltration was detected in the AD-like group and the AD-like group treated with vehicle (PL-407), where the 15d-PGJ$_2$ hydrogel significantly decreased (P<0.05) such infiltration of mast cells into the skin when compared with AD-like and AD-like + PL-407 (Fig. 5). Moreover, the group treated with Tacrolimus 0.1% also decreased mast cell infiltration, although no statistically significant difference was detected when compared to both untreated groups. The data on mast cell counts is shown in Fig. 5.

Measurement of total plasma IgE level in AD-like skin lesion. High IgE levels are a major feature of AD and those diagnosed with AD often exhibit high levels of total IgE and also allergen-specific IgE. Serum levels of IgE in the AD-like group and AD-like treated with vehicle were significantly higher than that in the disease-free specimens (P<0.05). Moreover, topical administration of 15d-PGJ$_2$ hydrogel significantly reduced the serum levels of IgE (P<0.05) compared to AD-like groups (Fig. 6).

Effect of 15d-PGJ$_2$ hydrogel on ROR-$\gamma$ expression in rat skin tissue. To determine whether 15d-PGJ$_2$ hydrogel decreases Th17 type lymphocyte, we performed immunohistochemistry to quantify the transcription factor ROR-$\gamma$ (Fig. 4). We found that topical administration of 15d-PGJ$_2$ hydrogel significantly decreased the number of immunostained cells compared to the AD-like group (P<0.05). No significant difference was observed between the AD-like group and the Tacrolimus-treated group (P>0.05), nor was it observed between the 15d-PGJ$_2$ hydrogel and the Tacrolimus groups (P>0.05). The data are shown in Fig. 7A.

Effect of 15d-PGJ$_2$ hydrogel on TNF-$\alpha$ expression in rat skin tissue. Immunohistochemistry was performed to verify whether 15d-PGJ$_2$ hydrogel would reduce TNF-$\alpha$ expression (Fig. 4). The number of immunostained cells in the AD-like group and the AD-like group treated with vehicle significantly increased in comparison to the disease-free specimens (P<0.05). Moreover, topical administration of 15d-PGJ$_2$ hydrogel significantly reduced the TNF-$\alpha$-positive cell count from the AD-like groups (P<0.05). It is important to highlight that no significant difference was detected between the AD-like group and the Tacrolimus-treated group (P>0.05). The data are described in Fig. 7B.

Discussion

The prostaglandin known as 15d-PGJ$_2$ is an endogenous PG that binds to PPAR-$\gamma$ generated during the resolution phase of inflammation following tissue injury (13) and it has shown a potent anti-inflammatory action when administrated exogenously (10,14,15). Moreover, improved bioavailability and efficiency of such compound has been achieved from different strategies to couple the 15d-PGJ$_2$ molecule to carrier systems (9,16,17). In this study, we demonstrated that topical administration of 15d-PGJ$_2$ hydrogel had a beneficial effect on AD symptoms, suggesting a potentially useful role for this formulation in the management of AD.

Considering that micellar dimensions were reduced at physiological temperature, micelles can remain at the site of administration for long periods of time and be small enough (<100 nm) to avoid uptake by the reticuloendothelial system, favoring the therapeutic efficacy of the drug carrier (18). In fact, for PL systems (such as PL 407), reductions on micellar hydrodynamic diameters in response to temperature changes are well-described in the literature. This phenomenon is attributed to the dehydration of PL polyoxypropylene oxide units from micellar core, reducing the micellar dimensions and promoting the formation of a colloidal system with spherical and almost identical micelles (19-21).

PL407 is a relatively hydrophilic PL type with hydrophilic lipophilic balance value of 22, due to differences on its polyethylene oxide (PEO) and polypropylene oxide (PPG) units number. The 1:3 units PEO:PPO relationship characterize its chemical structure making possible the formation of both
micellar hydrophobic core and hydrophilic corona capable of self-organization in a hydrogel supramolecular structure, responding to the presence of different molecules according to their chemical structure (22). Fig. 8 presents the sol-gel transition phenomena from PL unimers to micelles and their self-assembly as hydrogels in response to concentration and temperature, forming a final hydrogel formulation proposed here. Calorimetry analysis showed no significant shifts regarding to temperature for micelles formation. However, differences were observed for enthalpy variation value after 15d-PGJ2 incorporation, showing the drug interference on micellar self-assembly possibly due to its insertion into the system, as also described for different hydrophobic molecules (23-25). One of the main advantages of this system is the ability to incorporate hydrophobic molecules. Then, the hydrophobicity of the PL micellar core (due to polypropylene oxide units dehydration) and the 15d-PGJ2 chemical structure, as a low molecular weight prostanoid derivative (molecular weight of 316.4, C20H28O3), are important features for favoring its incorporation into PL407 micelles, explaining the high 15d-PGJ2 DL and encapsulation efficiency percentages. Additionally, no changes were observed on thermoreversible transitions.
properties, indicating the stability of the hydrogel systems after 15d-PGJ₂ incorporation. Rheological analysis provided important information regarding the sol-gel process kinetics, showing the formation of a structurally ordered and viscous hydrogel due to the predominance of elastic over viscous properties and increased viscosity values after 15d-PGJ₂ incorporation. The 15d-PGJ₂-loaded hydrogels showed low release constant value determined by the drug dissolution rate and its permeation during the hydrogel polymeric matrix erosion. This mechanism contributes to the formation of hydrated matrices due to the water penetration across the polymer chains (23,26).

In this study, we presented the development of a topical hydrogel formulation for AD based on 15d-PGJ₂-loaded PL407 hydrogel. The in vitro assays showed an extended release profile, being possible to predict that low 15d-PGJ₂ concentrations could be in contact to the site of application. According to the pharmacological daily scheme proposed here, a hydrogel volume of 3 µl was applied providing a 15d-PGJ₂ final concentration of 75 ng in contact to the skin area lesions. Since ~60% of encapsulated 15d-PGJ₂ was quantified after 24 h, that concentration was sufficiently released from hydrogels formulation explaining the formulation efficiency in terms of available drug concentration, despite the differences between in vitro and in vivo studies.

Regarding to molecular mechanism for AD treatment, there are two main concerns: the first is that AD is a chronic disease and long-term topical steroid use may lead to skin atrophy (27) and the second is that calcineurin inhibitors do not affect skin thickness but carry an increased risk of inducing skin cancer (28). We have demonstrated that topical administration of 15d-PGJ₂ hydrogel significantly reduced mast cell infiltration into the skin, reinforced by the fact that the outer aspect of the epidermis on the treated animals looked visibly normal (Figs. 4 and 5). A previous study showed that subcutaneous administration of 15d-PGJ₂ suppressed Bleomycin-induced skin sclerosis, despite no significant suppression of mast cell infiltration, but significant inhibition of the mast cell activation process (29). Furthermore, 15d-PGJ₂ was found to inhibit a series of fibroblast-associated processes, such as TGF-β stimulation of collagen gene expression, transdifferentiation of myofibroblasts (30) as well as the Smad-dependent promoter activity (31). 15d-PGJ₂ has also been shown to attenuate the proliferation of keloid cells, inhibit collagen gel contraction as well as to increase cleavage of caspase-3 (32). It has been demonstrated, however, that 15d-PGJ₂ and a prostanoid DP2 receptor agonist (13,14-dihydro-15-keto-prostaglandin D2) had no clear effect on the scratching behavior of rodents, thus suggesting that such prostaglandin D2 suppressive effect ought to be mediated by the prostanoid DP1 receptor instead (33).
A previous study demonstrated that 15d-PGJ2 is able to reduce IgE levels and inhibit the proliferation of LPS-induced B cells in an asthma-like model (34). Furthermore, 15d-PGJ2 was able to reduce FcERI expression, thus bypassing IgE binding to cells, which in turn decreased the secretion of important allergic inflammation activators (35). Additionally, previous reports have shown that 15d-PGJ2 can inhibit the IgE-switch in B-cells by suppressing the phosphorylation of STAT-6 (36). Corroborating with this previous findings, we showed that both treatments (15d-PGJ2 hydrogel or Tacrolimus 0.1%) significantly reduced systemic IgE levels when compared to the AD-like group. Beyond that, 15d-PGJ2 hydrogel or Tacrolimus 0.1% groups showed no difference when compared each other.

The role of the Th17 pathway has recently been extensively explored in chronic inflammatory illnesses. While a fundamentally autoimmune role has been associated with activation of the Th17 pathway (37,38), emerging data suggest that IL-17 and Th17 participate in the pathogenesis of AD, where IL-17 expression is upregulated in patients with acute AD lesions (39). Furthermore, Koga et al (40) have shown a correlation between circulating Th17 cells and the severity of acute AD. Besides, AD is considered a biphasic inflammation, in which Th2-mediated disease is predominant in the acute phase, switching towards the Th1-Th17 environment in chronic disease (41). Activated immune cells (macrophages and T cells) secrete TNF-α, which may also be produced by mast cells in response to IgE (42). Our data have shown that 15d-PGJ2 hydrogel was able to decrease the Th17 population at the site of AD, whereas Tacrolimus 0.1% failed to do so. This is a highly relevant observation, since IL-17 plays its part in modulating immune dysregulation and affecting the integrity of the skin barrier (43). Furthermore, upregulation of IL-17 in situ and circulating interleukin levels in AD reiterates the systemic inflammatory nature of such condition (44). Additionally, a significantly decreased in TNF-α expression was observed in group treated with 15d-PGJ2 hydrogel but not with Tacrolimus 0.1%. This an important finding since it is well-known that TNF-α is a key accessory mediator of T cell activation in AD.

As 15d-PGJ2 may have multiple effects on animal models of AD, more studies are needed to fully elucidate its role on treating allergic diseases. The PPAR-γ pathway may be one such target, since previous studies have shown that 15d-PGJ2 activation of PPAR-γ has an anti-inflammatory effect in an asthma model, which is yet another atopic condition (45). The present study clearly shows that 15d-PGJ2 hydrogel was able to suppress the progression of DNBC-induced AD. In addition, IgE levels decreased as well as Th17 and TNF-α positive cells. The emerging of a possible new treatment for AD that could be as effective as the current available with potentially fewer side-effects and a wider spectrum of action in the mechanism of atopic inflammation should be evaluated in a clinical trial. In conclusion, this new formulation of 15d-PGJ2 hydrogel may be a useful strategy in the management of AD.

Acknowledgements

Not applicable.

Funding

The authors are grateful to the Brazilian National Council for Scientific and Technological Development (CNPq), the São Paulo Research Foundation (FAPESP) and the Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES) for their financial support. MHN, JTC-N and DRA were supported by a research fellowship (grant nos. 303493/2016-0 and 309207/2016-9, respectively).

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors' contributions

MHN, AJDPJ and DRA designed the study. CGM and HBA performed the animal model experiments. NMM, MEAJ, PHBCA, ABS and MS acquired the data. MHN, JTCN, ABS, MS and DRA analyzed and interpreted the data, and drafted the manuscript. All authors critically revised the manuscript, and read and approved the final version of the manuscript.

Ethics approval and consent to participate

All animal experimental procedures and protocols were approved by the Committee on Animal Research of the University of Campinas (approval no. 4088-1) and are in accordance with guidelines of CONCEA.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

1. Veiga SP: Epidemiology of atopic dermatitis: A review. Allergy Asthma Proc 33: 227-234, 2012.
2. De Benedetto A, Kabo A and Beck LA: Skin barrier disruption: A requirement for allergen sensitization? J Invest Dermatol 132: 949-963, 2012.
3. Berke R, Singh A and Guralnick M: Atopic dermatitis: An overview. Am Fam Physician 86: 35-42, 2012.
4. Dhar S, Seth J and Parikh D: Systemic side-effects of topical corticosteroids. Indian J Dermatol 59: 460-464, 2014.
5. Margolis DJ, Abuabara K, Hoffstad OJ, Wan J, Raimondo D and Bliwer WB: Association between malignancy and topical use of pimecrolimus. JAMA Dermatol 151: 594-599, 2015.
6. Broeders JA, Ahmed Ali U and Fischer G: Systematic review and meta-analysis of randomized clinical trials (RCTs) comparing topical calcineurin inhibitors with topical corticosteroids for atopic dermatitis: A 15-year experience. J Am Acad Dermatol 75: 410-419, 2016.
7. Kakawa Y, Narumiya S, Fukushima M, Wakatsuka H and Hayashi O: 9-Deoxy-delta 9, 12, 13,14-dihydroprostaglandin D2, a metabolite of prostaglandin D2 formed in human plasma. Proc Natl Acad Sci USA 81: 1317-1321, 1984.
8. Straus DS and Glass CK: Cyclopentenone prostaglandins: New insights on biological activities and cellular targets. Med Res Rev 21: 185-210, 2001.
9. Napimoga MH, da Silva CA, Carregaro V, Farmesi-de-Assunção TS, Duarte PM, de Melo NF and Francisco LF: Exogenous administration of 15d-PGJ2-loaded nanocapsules inhibits bone resorption in a model of osteoporosis. J Endocrinol 189: 1043-1052, 2011.

10. Macedo CG, Napimoga MH, Rocha-Neto LM, Abdalla HB and Clemente-Napimoga JT: The role of endogenous opioid peptides in the antiinflammatory effect of 15-deoxy-D12,14-prostaglandin J2 in the temporomandibular joint. Prostaglandins Leukot Essent Fatty Acids 110: 23-34, 2014.

11. Shibata T, Kakusha K, Matsubara Y, Inuzuka E, Nakashima F, Takahashi N, Kozai D, Mori Y and Uchida K: Identification of a prostaglandin D2 metabolite as a neuritogenesis enhancer targeting the TRPV1 ion channel. Sci Rep 16: 21261, 2016.

12. Kim SR, Che HS, Seo HS, Ku JM, Hong SH, Yoo HH, Shin YC and Cho S-G: Enhancement of bone healing and pain relief efficacy of chitosan extract-inulin hydrogels: 2,4-dinitrochlorobenzene-induced atopic dermatitis in BALB/c mice. Mediators Inflamm 2014: 391438, 2014.

13. Sury YJ, Na HK, Park JM, Lee HN, Woon IS and Kim DD: 15-Deoxy-A2,14-15d-prostaglandin J2, an electrolytic lipid mediator of anti-inflammatory and pro-resolving signaling. Biochim Pharmacol 82: 1335-1351, 2011.

14. Silva Quinteiro M, Henrique Napimoga M, Gomes Macedo C, Furtado Freitas F, Balassini Abdalla H, Bonfante R and Trindade Clemente-Napimoga J: 15-deoxy-D12,14-prostaglandin J2 reduces albumin-induced arthritis in temporomandibular joint of rats. Eur J Pharmacol 588-589, 2014.

15. Napimoga MH, Vieira SM, Dal-Secco D, Freitas A, Souto FO, Mestriner FL, Alves-Filho JC, Grespan R, Kawai T, Ferreira SH and Cunha FQ: Peroxosome proliferator-activated receptor-gamma ligand, 15-deoxy-Delta12,14-prostaglandin J2, reduces neutrophil migration and enhances the pro-inflammatory response of human neutrophils. J Inflamm (Lond) 110: 230-067, 2014.

16. Clemente-Napimoga JT, Moreira JA, Grillo R, de Melo NF, Francisco LF and Napimoga MH: 15d-PGJ2-loaded in nanocapsules enhance the antiinflammatory properties into rat temporomandibular hypernociception. Life Sci 90: 944-949, 2012.

17. Alves C, de Mello N, Fraceto LF, de Araújo DR and Napimoga D and Napimoga MH: Effects of 15d-PGJ2-loaded poly(D,L-lactide-co-glycolide) nanoparticles on the anti-inflammatory effect of 15-deoxy-Delta12,14-prostaglandin J2 in the temporomandibular joint. Prostaglandins Leukot Essent Fatty Acids 110: 23-34, 2014.

18. Gaumet M, Vargas A, Gurny R and Delie F: Nanoparticles for drug delivery. Curr Opin Chem Biol 41: 122-131, 2019.

19. Trindade Clemente-Napimoga JT, Moreira JA, Grillo R, de Melo NF, Francisco LF and Napimoga MH: 15d-PGJ2-loaded in nanocapsules enhance the antiinflammatory properties into rat temporomandibular hypernociception. Life Sci 90: 944-949, 2012.

20. Dumortier G, Grossiord JL, Agnely F and Chaumeil JC: A review on the role of endogenous opioid peptides in the immunopathogenesis of atopic dermatitis. J Eur Acad Dermatol Venereol 21: 122-131, 1993.

21. Mills CM and Marks R: Side effects of topical glucocorticoids. Curr Probl Dermatol 21: 122-131, 1997.

22. Monteiro F, Alves‑Filho JC, Grespan R, Kawai T, Ferreira SH and Cunha FQ: Peroxosome proliferator-activated receptor-gamma ligand, 15-deoxy-Delta12,14-prostaglandin J2 and retrovasically transferred prostaglandin D synthase in a mouse model of bleomycin-induced scleroderma. Biomed Pharmacother 60: 18-25, 2006.

23. Kon K, Ikekima K, Hirose M, Yoshikawa M, Enomoto N, Kitamura T, Takei S, Hato N: Proglibotin prevents early-phase hepatic fibrogenesis caused by carbon tetrachloride. Biochem Biophys Res Commun 291: 55-61, 2002.

24. Ghosh AK, Bhattacharyya S, Lakos G, Chen SJ, Mori Y and Varga J: Disruption of transforming growth factor beta signaling and pro-resolving responses in normal skin fibroblasts by peroxisome proliferator-activated receptor gamma. Arthritis Rheum 50: 1305-1318, 2009.

25. Mantel A, Newsome A, Thekkudan T, Frazer R and Kadare M: The role of aldo-keto reductase 1C3 (AKR1C3)-mediated prostaglandin D2 (PGD2) metabolism in keloids. Exp Dermatol 25: 38-43, 2016.

26. Ari I, Takano N, Hashimoto Y, Futaki N, Sugimoto M, Takahashi N, Inoue T and Nakae S: Prostanoid DP1 receptor agonist inhibits the pruritic activity in NC/Nga mice with atopic dermatitis. Eur J Pharmacol 505: 229-235, 2004.

27. Farmesi-de-Assunção TS, Alves CF, Carregaro V, de Oliveira JR, da Silva CA, Cerraiinzon HH, Cunha FQ and Napimoga MH: PPARγ agonists, mainly 15d-PGJ2), reduce eosinophil recruitment following allergen challenge. Cell Immunol 273: 23-29, 2012.

28. Fujiyama Y, Tachibana H and Yamada K: Peroxisome proliferator-activated receptor ligands negatively regulate the expression of the high-affinity IgE receptor Fc epsilon RI in human basophilic KU812 cells. Biochem Biophys Res Commun 297: 193-202, 2002.

29. Miyazaki Y, Tachibana H and Yamada K: Inhibitory effect of peroxisome proliferator-activated receptor-gamma ligands on the expression of toll-like receptor 9 in human monocytes. J Immunol 189: 21261, 2016.

30. Toda M, Leung DY, Molet S, Boguniewicz M, Taha R, Christodouloupolous F, Fukuda T, Elías JA and Hamid QA: Polarized in vivo expression of IL-11 and IL-17 between acute and chronic skin lesions. J Allergy Clin Immunol 111: 875-881, 2003.

31. Koga C, Kashiwaba K, Shiraihi N, Kobayashi M and Tokura Y: Possible pathogenic role of Th17 cells for atopic dermatitis. J Invest Dermatol 128: 2625-2630, 2008.

32. Di Cesare A, Di Miglio P and Nestle FO: A role for Th17 cells in the immunopathogenesis of atopic dermatitis? J Invest Dermatol 128: 2569-2571, 2008.

33. Theoharides TC, Alysandratos KD, Angelidou A, Delivianis DA, Sismanopoulos N, Zhang B, Asadi S, Vasiadi M, Weng P, Miniati A and Kalogeromitros D: Mast cells and inflammation. Biochim Biophys Acta 1822: 21-33, 2015.

34. Farnesi-de-Assunção TS, Alves CF, Carregaro V, de Oliveira JR, da Silva CA, Cerraiinzon HH, Cunha FQ and Napimoga MH: PPARγ agonists, mainly 15d-PGJ2), reduce eosinophil recruitment following allergen challenge. Cell Immunol 273: 23-29, 2012.

35. Fujiyama Y, Tachibana H and Yamada K: Peroxisome proliferator-activated receptor ligands negatively regulate the expression of the high-affinity IgE receptor Fc epsilon RI in human basophilic KU812 cells. Biochem Biophys Res Commun 297: 193-202, 2002.

36. Miyazaki Y, Tachibana H and Yamada K: Inhibitory effect of peroxisome proliferator-activated receptor-gamma ligands on the expression of toll-like receptor 9 in human monocytes. J Immunol 189: 21261, 2016.

37. Toda M, Leung DY, Molet S, Boguniewicz M, Taha R, Christodouloupolous F, Fukuda T, Elías JA and Hamid QA: Polarized in vivo expression of IL-11 and IL-17 between acute and chronic skin lesions. J Allergy Clin Immunol 111: 875-881, 2003.

38. Koga C, Kashiwaba K, Shiraihi N, Kobayashi M and Tokura Y: Possible pathogenic role of Th17 cells for atopic dermatitis. J Invest Dermatol 128: 2625-2630, 2008.

39. Di Cesare A, Di Miglio P and Nestle FO: A role for Th17 cells in the immunopathogenesis of atopic dermatitis? J Invest Dermatol 128: 2569-2571, 2008.